Saturna Capital’s Dr. Reddy's Laboratories RDY Stock Holding History

Saturna Capital’s Portfolio RDY Stock Details RDY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q1	–	Sell	-60,000	Closed	-$451K	–	160
2017 Q4	$451K	Sell	60,000 -32,500	-35%	-$234K	0.01%	130
2017 Q3	$660K	Buy	92,500 +5,250	+6%	+$37.7K	0.02%	117
2017 Q2	$735K	Sell	87,250 -3,500	-4%	-$28.5K	0.02%	112
2017 Q1	$729K	Buy	90,750 +1,750	+2%	+$15.1K	0.02%	112
2016 Q4	$806K	Sell	89,000 -1,500	-2%	-$14K	0.03%	112
2016 Q3	$840K	Hold	90,500	–	–	0.03%	112
2016 Q2	$927K	Buy	90,500 +29,390	+48%	+$269K	0.03%	108
2016 Q1	$549K	Buy	61,110 +60,000	+5,405%	+$536K	0.02%	135
2015 Q4	$10K	Buy	+1,110	New	+$12.2K	﹤0.01%	319
2014 Q2	–	Sell	-75,000	Closed	-$631K	–	404
2014 Q1	$659K	Hold	75,000	–	–	0.02%	159
2013 Q4	$615K	Hold	75,000	–	–	0.02%	170
2013 Q3	$567K	Buy	75,000 +10,000	+15%	+$72.7K	0.02%	182
2013 Q2	$492K	Buy	+65,000	New	+$475K	0.01%	185

Other funds holding RDY

Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

CBOA

Commonwealth Bank of Australia Sydney, NSW, Australia $231M AUM

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

MIP

Mondrian Investment Partners London, United Kingdom $6.69B AUM

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return

Saturna Capital's RDY Position: Q1 2018 in Review

Saturna Capital sold out of Dr. Reddy's Laboratories (RDY) in Q1 2018, closing a stake of 60,000 shares — an estimated $451K sold.

Saturna Capital first reported a position in RDY in Q2 2013 and held it in 13 quarters. The position peaked at $927K in Q2 2016. 121 funds tracked by Wall St. Rank hold RDY as of Q1 2018.

Saturna Capital reported no remaining Dr. Reddy's Laboratories position as of Q1 2018 after selling out during the quarter.
Saturna Capital sold 60,000 Dr. Reddy's Laboratories shares in Q1 2018, an estimated $451K.
Saturna Capital first reported a position in Dr. Reddy's Laboratories in Q2 2013 and held it in 13 quarters.
Saturna Capital's Dr. Reddy's Laboratories position peaked at $927K in Q2 2016.
121 funds tracked by Wall St. Rank held Dr. Reddy's Laboratories as of Q1 2018.

Based on Saturna Capital's 13F filing for Q1 2018, filed 10 May 2018.